An open study of botulinum-A toxin treatment of trigeminal neuralgia.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 16247065.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Thirteen subjects with trigeminal neuralgia were treated with botulinum-A neurotoxin (BoNT/A) in an open-label pilot study. After BoNT/A, visual analog scale score, surface area of pain, and therapeutic coefficient were reduced in all patients and for all branch trigeminal nerves studied. Therefore, BoNT/A is an efficient treatment. There were no major side effects. A placebo-controlled clinical trial is needed to confirm these findings.
Medical subject headings
- Botulinum Toxins, Type A
- Trigeminal Nerve
- Trigeminal Neuralgia